Hand ScleroDerma Lived Experience Scale in Individuals With Systemic Sclerosis
Investigation of the Turkish Validity and Reliability of the Hand ScleroDerma Lived Experience Scale (HAnDE Scale) Questionnaire in Individuals With Systemic Sclerosis
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Denizli, Turkey (Türkiye)
- Pamukkale University
-
-
Malatya
-
Malatya, Malatya, Turkey (Türkiye)
- Inonu University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Being diagnosed with Systemic Sclerosis by a rheumatologist
- Being 18 years of age or older,
Exclusion Criteria:
- Presence of neurological disease
- Presence of any orthopedic problem that will affect functionality
- Presence of orthopedic surgery history
- Inability to speak or understand Turkish fluently.
- Presence of psychiatric disease that will affect cooperation.
- Severe neurological disease that will affect hand functions (peripheral nerve lesion, trauma, operation, cerebrovascular accident).
- Heart failure and lung pathology that will affect daily living activities.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Hand ScleroDerma Lived Experience Scale (HAnDE Scale) Questionnaire
Time Frame: Evaluations started immediately after receiving ethics committee approval and will be completed within 6 months, which is the study period.
|
The scale consists of 18 items regarding the patient-reported status of hand function in individuals with SSc.
Each response ranges from 0 to 4. 0 means 'completely disagree' and 4 means 'completely agree'.
The higher the scale score, the worse the experience with the hand
|
Evaluations started immediately after receiving ethics committee approval and will be completed within 6 months, which is the study period.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Hand Mobility in Scleroderma Test
Time Frame: Evaluations started immediately after receiving ethics committee approval and will be completed within 6 months, which is the study period.
|
It is a functional test that evaluates hand mobility.
It evaluates 4 specific movements for the hand.
These are extension, flexion, finger abduction and wrist dorsal extension.
Various objects are used for evaluations, including cutting tool handles, pens, coffee packages, coils of rope, milk packages and tables.
Each movement is scored between 0 and 3. 0 is used for being able to perform the movement normally and 3 for being completely unable to perform it.
The total score is calculated by adding the scores for each movement and the highest score is 12.
|
Evaluations started immediately after receiving ethics committee approval and will be completed within 6 months, which is the study period.
|
|
Scleroderma Skin Involvement: Patient-Reported Outcomes
Time Frame: Evaluations started immediately after receiving ethics committee approval and will be completed within 6 months, which is the study period.
|
Scleroderma Skin Involvement: Patient-Reported Outcomes was developed to assess skin-related quality of life in patients with systemic sclerosis.
SSPRO consists of four domains: physical impact, emotional impact, physical limitation, and social impact, and consists of 18 items in total.
Items are rated on a 6-point scale from no disability (0 points) to severe disability (6 points).
The scores are added together to calculate a final score (0 to 108 points).
A lower score indicates a much better quality of life
|
Evaluations started immediately after receiving ethics committee approval and will be completed within 6 months, which is the study period.
|
|
Modified Rodnan Skin Thickness Score
Time Frame: Evaluations started immediately after receiving ethics committee approval and will be completed within 6 months, which is the study period.
|
This method used to assess skin thickness in SSc.
The Modified Rodnan Skin Thickness Score assesses skin thickness from 17 body regions.
A score of 0 indicates normal skin thickness, 1 indicates mild skin thickness, 2 indicates moderate skin thickness, and 3 indicates severe skin thickness; a score of 3 indicates that the skin layers cannot be made between two fingers.
The score is calculated by summing the scores from all 17 regions (range 0-51)
|
Evaluations started immediately after receiving ethics committee approval and will be completed within 6 months, which is the study period.
|
|
Scleroderma Health Assessment Questionnaire
Time Frame: Evaluations started immediately after receiving ethics committee approval and will be completed within 6 months, which is the study period.
|
Used to assess disease activity.
It has 20 items in 8 sections assessing physical disability.
In addition, Raynaud phenomenon, digital ulcers, pulmonary and gastrointestinal symptoms are assessed according to the Visual Analog Scale, which is scored between "0" and "10".
VAS is scored between 0 and 3 by multiplying by 0.2
|
Evaluations started immediately after receiving ethics committee approval and will be completed within 6 months, which is the study period.
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- Validity and Reliability
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.